Tag: science
-
The landscape of AI drug-discovery platforms: the design is proven, but is the clinic?
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. AI drug-discovery platforms (Recursion, Insilico, Isomorphic, Schrödinger, Relay, Nimbus and others) have partly proven that they can design and optimize molecules — many candidates have entered the clinic and…
-
Finerenone and the CKM “third pillar” — complementarity is a division of outcomes, and the anti-fibrotic expansion is preclinical-thick but human-empty
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone completes the cardio-kidney-metabolic (CKM) “three-pillar” standard of care alongside SGLT2 inhibitors and GLP-1 agonists through a non-overlapping anti-inflammatory / anti-fibrotic axis. But the real substance…
-
The clinical cost behind the finerenone headline — hyperkalemia, modest absolute benefit, and the real-world monitoring gap, by evidence tier
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Behind finerenone’s headline hazard ratios sits a clinical cost that is not dramatic harm but friction. Across RCTs, hyperkalemia occurs at roughly 2× the placebo…
-
Finerenone’s commercial moat (Part 3): “the only nonsteroidal MRA with hard-outcome trials” — a real but time-limited advantage boxed in on three sides
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment or medical advice. The 30-second version What. Finerenone (Bayer’s Kerendia) is currently the only nonsteroidal MRA (nsMRA) with hard-outcome RCT evidence. That single fact is its commercial moat: every competitor is on a surrogate…
-
The three-pillar combination in CKM — where the finerenone + SGLT2i + GLP-1 case is proven, and where it is still an assumption
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The “three-pillar” combination in cardio-kidney-metabolic (CKM) disease stacks three non-overlapping mechanisms — SGLT2 inhibitor (hemodynamic), GLP-1 receptor agonist (metabolic) and finerenone (anti-inflammatory / anti-fibrotic). CONFIDENCE (NEJM…
-
Does finerenone move hard outcomes, or mainly organ and morbidity endpoints? A close read of FIDELITY, FINEARTS-HF and FINE-HEART
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduced kidney and heart-failure morbidity endpoints consistently across three pooled trial layers. But the single hardest endpoint, cardiovascular death,…
-
The finerenone landscape — a nonsteroidal MRA as the third pillar of CKM care, and what is still an open question
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation and fibrosis rather than blood pressure and volume — a mechanism that does not overlap…
-
The clinical cost behind the GLP-1 headline — reading lean-mass loss, discontinuation, rebound, and safety signals by evidence tier
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. The GLP-1/GIP headline of −15 to −20% body weight comes with clinical costs: loss of lean (fat-free) mass, real-world discontinuation (roughly 50%+ within a year),…
-
The GLP-1 commercial map (Part 3): not “who wins” but “who gets access” — the Novo–Lilly duopoly and the access bottleneck
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. In the 2025–26 GLP-1 commercial map, US prescription share has flipped: Lilly (tirzepatide) overtook Novo (semaglutide) — roughly 57%+ vs 43% of US scripts as of Q3 2025 (press…
-
The next-generation obesity pipeline: from “how much you lose” to “at what cost”
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The next-generation obesity drugs push weight-loss efficacy along three vectors: triple agonists (retatrutide), oral small molecules (orforglipron), and amylin combinations (CagriSema). At the top end, retatrutide’s…
Uthando Nethemba 